Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts.
Akselband
Y
Y
Immunology and Cell Biology, Vertex Pharmaceuticals Inc, Cambridge, MA 02139-4211.
Harding
M W
MW
Nelson
P A
PA
D016475:3T3 Cells; D000818:Animals; D001011:Aorta; D002417:Cattle; D002455:Cell Division / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology*; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000166:cytology* / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007700:Kinetics; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D051379:Mice; D011090:Polyenes / Q000494:pharmacology*; D020123:Sirolimus; D016559:Tacrolimus / Q000494:pharmacology*
D007166:Immunosuppressive Agents; D011090:Polyenes; D016222:Fibroblast Growth Factor 2; D016572:Cyclosporine; D020123:Sirolimus; D016559:Tacrolimus